MedPath

Magnetic Resonance Angiography for Peripheral Arterial Disease (PAD)

Phase 2
Conditions
Peripheral Arterial Disease (PAD)
Interventions
Registration Number
NCT00707876
Lead Sponsor
AMAG Pharmaceuticals, Inc.
Brief Summary

The purpose of this study is to compare the difference between two magnetic resonance imaging (MRI) techniques for visualizing arteries. The study hypothesizes that one method that relies upon imaging flowing blood in the pelvic and leg arteries will not be as accurate or efficient as injecting a safe imaging agent to change the appearance of the blood on the MRI. Both methods will be compared with Digital Subtraction Angiography (DSA).

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
108
Inclusion Criteria
  • Subjects with symptoms of PAD
  • Scheduled for DSA
Exclusion Criteria
  • Critical leg ischemia manifested by ulcers, gangrene or leg amputation
  • Laboratory evidence of iron overload, liver disease, pregnancy
  • History of allergy to or recent exposure to radiocontrast, gadolinium chelates, or intravenous iron therapy
  • Clinical concerns about co-morbidities, subject suitability

Study & Design

Study Type
INTERVENTIONAL
Study Design
FACTORIAL
Arm && Interventions
GroupInterventionDescription
1ferumoxytolDose 1 versus non-contrast MRA
2ferumoxytolDose 2 versus non-contrast MRA
3ferumoxytolDose 3 versus non-contrast MRA
Primary Outcome Measures
NameTimeMethod
To assess sensitivity and specificity of non-contrast MRA and VE-MRI at three ferumoxytol dosing levels3 weeks
Secondary Outcome Measures
NameTimeMethod
To assess positive and negative predictive values of VE-MRI using ferumoxytol at different dosing levels.3 weeks
© Copyright 2025. All Rights Reserved by MedPath